| Literature DB >> 24552436 |
Danica D Vance1,2, Gordon L Chen2, Mark Stoutenberg3,4, Robert J Myerburg2,5, Kevin Jacobs3, Lubov Nathanson1, Arlette Perry3, David Seo1,6, Pascal J Goldschmidt-Clermont1,2, Evadnie Rampersaud1,6.
Abstract
BACKGROUND: The mechanisms through which exercise reduces cardiovascular disease are not fully understood. We used echocardiograms, cardiac biomarkers and gene expression to investigate cardiovascular effects associated with exercise training.Entities:
Year: 2014 PMID: 24552436 PMCID: PMC3996079 DOI: 10.1186/2052-1847-6-6
Source DB: PubMed Journal: BMC Sports Sci Med Rehabil ISSN: 2052-1847
Figure 1Study design.
Training group and control changes at baseline versus 16 weeks (n=22)
| | | ||||||
|---|---|---|---|---|---|---|---|
| Weight | 196.76±28.40 | 192.85±27.60 | 0.08 | 188.31±26.11 | 190.11±26.41 | .064 | 0.316 |
| Heart rate | 76.71±12.41 | 67.60±11.76 | 0.002 | 73.18±12.75 | 76.05±15.99 | .357 | 0.363 |
| Systolic BP (mmHg) | 121.62±8.45 | 114.30±9.23 | 0.0001 | 116.67±9.86 | 113.36±7.26 | .133 | 0.088 |
| Diastolic BP (mmHg) | 80.05±9.70 | 73.15±8.20 | 0.007 | 75.67±8.46 | 77.14±5.20 | .542 | 0.127 |
| Relative VO2 max | 37.06±7.12 | 42.02±8.81 | 0.00004 | 38.83±5.03 | 39.02±6.74 | .813 | 0.35 |
| Body fat (%) | 29.51±8.33 | 28.18±8.86 | 0.044 | 26.84±6.84 | 27.45±6.87 | .116 | 0.256 |
| HDL | 46.71±9.61 | 43.10±6.37 | 0.055 | 49.59±7.87 | 47.05±9.15 | .183 | 0.288 |
| LDL | 107.05±25.64 | 103.80±28.03 | 0.44 | 100.23±22.39 | 105.86±20.61 | .087 | 0.358 |
| Triglycerides | 119.90±59.41 | 116.35±72.01 | 0.997 | 85.05±38.84 | 77.68±40.87 | .294 | 0.03 |
| CRP | 1.92±2.66 | 1.64±1.92 | 0.752 | 0.84±0.66 | 1.03±0.83 | .269 | 0.084 |
| Troponin T | <0.01 | <0.01 | 0.333 | <0.01 | <0.01 | .333 | 1 |
*Difference in variable measures between baseline and peak. **Difference at baseline between Training and Control groups.
Echocardiographic changes over 16 weeks (n=19)
| | ||||||
|---|---|---|---|---|---|---|
| Interventricular septum in diastole (cm) | 0.925±0.102 | 1.003±0.128 | 0.028 | 0.925±0.115 | 0.982±0.138 | 0.074 |
| Left ventricular internal diameter in diastole (cm) | 4.803±0.490 | 4.818±0.490 | 0.864 | 4.726±0.409 | 4.876±0.451 | 0.067 |
| Left ventricular posterior wall in diastole (cm) | 0.961±0.092 | 1.075±0.123 | 0.003 | 0.930±0.134 | 0.963±0.133 | 0.439 |
| Left ventricular mass (g) | 186.6±37.4 | 209.2±30.0 | 0.009 | 183.0±31.1 | 192.1±32.2 | 0.114 |
| Left ventricular mass index (g/m2) | 91.4±16.8 | 102.8±12.8 | 0.008 | 90.4±15.1 | 94.2±14.1 | 0.194 |
| Left ventricular end-diastolic volume (ml) | 118.4±23.8 | 144.1±29.6 | 0.002 | 124.7±32.7 | 133.1±30.8 | 0.186 |
| Left ventricular end-systolic volume (ml) | 45.8±16.4 | 52.4±16.7 | 0.195 | 43.4±14.0 | 48.0±14.8 | 0.11 |
| Ejection fraction (%) | 61.9±7.9 | 63.8±7.8 | 0.461 | 65.2±6.5 | 64.2±6.5 | 0.47 |
| Stroke volume (ml) | 72.6±14.0 | 91.6±20.9 | 0.001 | 81.2±22.3 | 85.1±20.4 | 0.411 |
| Peak early to late mitral annular velocities (E to A ratio) | 1.59±0.37 | 1.38±0.40 | 0.03 | 1.67±0.43 | 1.70±0.48 | 0.766 |
Table 1 shows comparison of echocardiographic changes between TRAIN and CON groups. The following significant changes occurred in the TRAIN group: (1) interventricular septal thickness increased from 0.925±0.102 cm to 1.003±0.128 cm (p=0.028), (2) posterior wall thickness in diastole increased from 0.961±0.092 cm to 1.075±0.123 cm (p=0.003), (3) LV mass increased from 186.6±37.4 g to 209.2±30.0 g (p=0.009), (4) LV mass index increased from 91.4±16.8 g/m2 to 102.8±12.8 g/m2 (p=0.008), (5) LV end diastolic volume increased from 118.4±23.8 ml to 144.1±29.6 ml (p=0.002), (5) stroke volume increased from 72.6±14.0 ml to 91.6±20. 9ml (p=0.001), and (6) the E to A ratio decreased from 1.59±0.37 to 1.38±0.40 (p=0.03). No significant changes occurred within the control group from baseline to 16 week follow-up.
Genes with significantly increased expression levels in active (TRAIN) vs. sedentary (CON) individuals (FDR <0.05)
| 7966089 | CMKLR1 | 1.56 |
| 7975779 | FOS | 1.74 |
| 7929065 | IFIT1 | 1.51 |
| 8141094 | PDK4 | 1.53 |
| 7929256 | --- | 1.6 |
| 7928306 | --- | 1.64 |
| 7966089 | CMKLR1 | 1.68 |
| 7906475 | FCRL6 | 1.66 |
| 7996081 | GPR56 | 1.55 |
| 7906764 | HSPA6 | 1.53 |
| 7964787 | IFNG | 1.66 |
| 8054722 | IL1B | 1.71 |
| 7961175 | KLRC3 | 1.64 |
| 7971661 | MIR15A | 1.8 |
*FDR= false discovery rate (p<0.05 threshold used).
Genes with decreased expression levels in active (TRAIN) vs. sedentary (CON) individuals
| 8102787 | --- | −1.5 |
| 8020825 | --- | −1.7 |
| 8037387 | --- | −1.65 |
| 8136471 | --- | −1.56 |
| 8104490 | --- | −1.56 |
| 8084810 | --- | −1.54 |
| 8095744 | AREG | −2.42 |
| 8095736 | AREG | −2.18 |
| 8062444 | BPI | −1.74 |
| 7961075 | CD69 | −1.69 |
| 8149116 | DEFA3 | −2.42 |
| 8149126 | DEFA3 | −2.42 |
| 8149137 | DEFA3 | −2.34 |
| 8084704 | EIF4A2 | −1.7 |
| 8158167 | LCN2 | −1.51 |
| 8086607 | LTF | −1.98 |
| 7951246 | MMP8 | −1.95 |
| 8012349 | PER1 | −1.59 |
| 7919269 | RNU1-1 | −1.55 |
| 7919349 | RNU1-1 | −1.55 |
| 7973896 | RNU1-1 | −1.53 |
| 7978568 | RNU1-1 | −1.53 |
| 7898375 | RNU1-1 | −1.52 |
| 7898411 | RNU1-1 | −1.52 |
| 7912800 | RNU1-1 | −1.52 |
| 7912850 | RNU1-1 | −1.52 |
| 7919576 | RNU1-1 | −1.52 |
| 7948894 | RNU2-1 | −1.53 |
| 7938295 | RPL27A | −1.51 |
| 8103975 | SLED1 | −1.62 |
| 7925182 | SNORA14B | −1.5 |
| 7968234 | SNORA27 | −1.52 |
| 7977075 | SNORA28 | −1.56 |
| 7938293 | SNORA45 | −1.6 |
| 8078918 | SNORA62 | −1.86 |
| 8059708 | SNORA75 | −2.03 |
| 8139456 | SNORA9 | −1.55 |
| 7968232 | SNORD102 | −1.67 |
| 8124940 | SNORD117 | −1.67 |
| 7942592 | SNORD15A | −1.53 |
| 8059710 | SNORD20 | −1.93 |
| 7903022 | SNORD21 | −1.69 |
| 8159004 | SNORD24 | −1.83 |
| 7948906 | SNORD27 | −1.69 |
| 7948904 | SNORD28 | −1.51 |
| 7948900 | SNORD30 | −1.8 |
| 8030364 | SNORD34 | −1.64 |
| 8159006 | SNORD36B | −1.78 |
| 8005951 | SNORD42B | −1.63 |
| 8005957 | SNORD4B | −1.63 |
| 8023259 | SNORD58A | −1.64 |
| 7964246 | SNORD59B | −1.56 |
| 8122265 | TNFAIP3 | −1.61 |
Genes with significant expression in high responders(n=10) vs. low responders** (n=9)
| 7969794 | LOC100132099 | −1.58 |
| 8049530 | LRRFIP1 | −1.58 |
| 7919269 | RNU1-1 | −1.89 |
| 7919349 | RNU1-1 | −1.89 |
| 7898375 | RNU1-1 | −1.86 |
| 7898411 | RNU1-1 | −1.86 |
| 7912800 | RNU1-1 | −1.86 |
| 7912850 | RNU1-1 | −1.86 |
| 7919576 | RNU1-1 | −1.86 |
| 7973896 | RNU1-1 | −1.85 |
| 7978568 | RNU1-1 | −1.85 |
| 7897801 | RNU5E | −1.89 |
| 7920873 | SNORA42 | −3.49 |
| 8117018 | --- | −1.86 |
| 7932635 | --- | −1.63 |
| 7965150 | --- | −1.62 |
| 8005225 | LOC162632 | 2.35 |
No genes met FDR significance criteria for differential mRNA expression in blood collected at baseline.
*High Responders are defined as those individuals who fell in the upper quartile (upper 25%) of percent change in rVO2 max.
**Low Responders are defined as those individuals who fell below the upper quartile of percent change in rVO2 max.